Phase 1 Peripheral Neuropathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 21 years old or older.
• You have symptoms of nerve damage caused by chemotherapy (such as pain, tingling, numbness, or muscle weakness) that have lasted more than 2 weeks.
• You completed a platinum-based chemotherapy treatment for colorectal, bile duct, pancreatic, esophageal, stomach, or small intestine cancer within the past 2 years.
• If you are currently taking any treatments for chemotherapy-related nerve damage, you are willing and able to stop taking them at least 2 weeks before joining the trial.
• If you are a woman who could become pregnant, you must have a negative pregnancy test before starting the trial.
• If you or your partner could become pregnant, you agree to use effective birth control or avoid sexual activity that could lead to pregnancy during the study and for at least 1 month after the last dose.
• You receive your care at Penn State Health.

Who may not be able to join:

• You are under 21 years of age.
• You had nerve damage (neuropathy) before you started chemotherapy.
• You are currently pregnant or breastfeeding.
• You have high blood pressure that is not well controlled even with medication, or you have low blood pressure (confirm with trial site).
• You have a history of, or currently have, a stroke or heart attack.
• You have taken part in another clinical drug trial or used an experimental drug within the past 30 days.
• Your liver test results have been significantly abnormal (more than 3 times the normal level) within the past year.
• You have had thoughts of suicide or have had uncontrolled depression within the past year.
• You have a known allergy or sensitivity to CBG/CBD hemp extract.
• You have a known allergy or sensitivity to coconut oil.
• You are currently receiving active cancer treatments such as chemotherapy, immunotherapy, or targeted therapy.
• You currently take certain medications that affect how your liver processes drugs (specifically, moderate or strong inhibitors or inducers of CYP3A4 or CYP2C19) (confirm with trial site).
• You currently take certain medications with a narrow safe dosage range that interact with the study drug, unless your doctor agrees to carefully monitor and adjust your dose (confirm with trial site).
• You currently take valproate or other medications known to raise the risk of liver problems when combined with cannabidiol (confirm with trial site).
• You currently take certain other medications that are processed by the liver in specific ways and cannot be safely monitored or adjusted during the trial (confirm with trial site).
• You currently take other medications known to be harmful to the liver, unless the study team has reviewed and accepted the risk (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.